Pacira BioSciences (NASDAQ: PCRX) posts preliminary 2025 revenue update

Rhea-AI Filing Summary

Pacira BioSciences, Inc. filed a current report stating that it has issued a press release with its preliminary, unaudited revenue for the fourth quarter and full year ended December 31, 2025. The company is sharing an early view of its 2025 revenue performance before final audited results are available.

The press release, dated January 8, 2026, is included as Exhibit 99.1. Pacira notes that this revenue information is being furnished rather than filed under securities laws, which limits how it is treated for certain liability and incorporation-by-reference purposes.

1/8/20260001396814false00013968142026-01-082026-01-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 8, 2026

PACIRA BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-35060

51-0619477

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

2000 Sierra Point Parkway, Suite 900

Brisbane, California 94005

(Address and Zip Code of Principal Executive Offices)

(650) 242-8052

(Registrant’s Telephone Number, Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading symbol

Name of each exchange on which registered

Common Stock, par value $0.001 per share

PCRX

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On January 8, 2026, Pacira BioSciences, Inc. issued a press release announcing its preliminary, unaudited revenue for the fourth quarter and full-year ended December 31, 2025. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

Exhibit Number						Description
99.1						Press Release dated January 8, 2026.
104						Cover Page Interactive Data File (Formatted as Inline XBRL)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

									PACIRA BIOSCIENCES, INC. (REGISTRANT)
Dated:			January 8, 2026			By:			/s/ KRISTEN WILLIAMS
									Kristen Williams
									Chief Administrative Officer and Secretary

FAQ

What did Pacira BioSciences (PCRX) report in this 8-K?

Pacira BioSciences, Inc. reported that it issued a press release announcing its preliminary, unaudited revenue for the fourth quarter and full year ended December 31, 2025, which is attached as Exhibit 99.1.

Which period does Pacira BioSciences’ preliminary revenue cover?

The preliminary, unaudited revenue disclosed by Pacira BioSciences covers the fourth quarter and the full year ended December 31, 2025.

Where can investors find the preliminary revenue details for Pacira BioSciences (PCRX)?

The specific preliminary revenue figures are contained in the press release that Pacira BioSciences furnished as Exhibit 99.1 to this report.

Is Pacira BioSciences’ preliminary revenue information considered filed with the SEC?

No. The company states that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities or automatically incorporated into other filings.

What exhibits are included with this Pacira BioSciences 8-K?

The report includes Exhibit 99.1, a press release dated January 8, 2026, and Exhibit 104, the cover page interactive data file formatted as Inline XBRL.

Who signed this Pacira BioSciences (PCRX) current report?

The report was signed on behalf of Pacira BioSciences, Inc. by Kristen Williams, who is the company’s Chief Administrative Officer and Secretary.